Get the Stockscreener App
2.21
1.34%
-0.03
After Hours:
2.17
-0.04
-1.81%
Therapeuticsmd Inc stock is traded at $2.21, with a volume of 7,785.
It is down -1.34% in the last 24 hours and up +8.33% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
See More
Previous Close:
$2.24
Open:
$2.23
24h Volume:
7,785
Relative Volume:
0.20
Market Cap:
$25.58M
Revenue:
$3.35M
Net Income/Loss:
$86,000
P/E Ratio:
143.51
EPS:
0.0154
Net Cash Flow:
$2.67M
1W Performance:
-0.45%
1M Performance:
+8.33%
6M Performance:
+2.31%
1Y Performance:
+104.63%
1-Day Range:
$2.18
$2.23
1-Week Range:
$2.17
$2.31
52-Week Range:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.21 | 23.84M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD (TXMD) Holds Steady at $2.22 as Traders Eye Tight Trading RangeLong Setup Ideas - vinanet.vn
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
THERAPEUTICSMD STOCK : BIG PRICE RECOVERY | TXMD STOCK Moon (nkL8YZ0GKj) - Mshale
TherapeuticsMD (TXMD) Quarterly Figures: EPS Falls Short of Its Estimate under the Current Snapshot; Post-Earnings: The Stock Ends Up 0.49% in the Latest ReadingPre-Announcement Alert - siam.in
TherapeuticsMD (TXMD) Range: Ends a Quiet Session at $2.06 in the Latest Reading; Levels: Traders Can Monitor the $1.96-$2.16 Range in the Available RecordHigh Volume Node - vinanet.vn
TherapeuticsMD (TXMD) Range: Moves 0.49% Down to $2.05; the Current Price Sits Inside the Supplied Technical Range for the Current SessionLiquidity Order Flow - vinanet.vn
TherapeuticsMD (TXMD) Results Review: The EPS Result Is Below Expectation for This Review; Post-Earnings: The Stock Records a 1.48% Increase at the CloseSegment Revenue Breakdown - vinanet.vn
TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD - TradingView
TherapeuticsMD(TXMD) Stock Options Chain | Quotes & News - Moomoo
TherapeuticsMD Company Profile & Introduction - Moomoo
TherapeuticsMD, Inc. Revenue Breakdown – DUS:29TA - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
TherapeuticsMD (TXMD) Holds Steady at $2.08 as Traders Eye Key Support and ResistanceBull Flag - vinanet.vn
TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year - clinicaltrialvanguard.com
TherapeuticsMD: Q2 Earnings Snapshot - AOL.com
TherapeuticsMD Q2 Net Income From Cont Ops US - Moomoo
TherapeuticsMD Q2 EPS drops 80% to $0.01 on sales slide - scanx.trade
Is TherapeuticsMD Inc (TXMD) Positioned for Growth After Q2 Earn - GuruFocus
TherapeuticsMD Q2 Results and Strategic Alternatives Review - TipRanks
TherapeuticsMD, Inc. Q2 2026: Revenue $869K, EPS $0.01— 10-Q Summary - TradingView
TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives - TradingView
TherapeuticsMD Q2 2026 License Revenue Falls to $869000 - Quiver Quantitative
TherapeuticsMD | 10-Q: Q2 2026 Earnings Report - Moomoo
TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline - TradingKey
TXMD: Q2 2026 saw lower net income and license revenue, with strategic alternatives under evaluation - TradingView
TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives - Stock Titan
TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan
TherapeuticsMD, Inc. (29TA.SG) stock price, news, quote and history - Yahoo Finance Australia
TXMD Q3 2023 Earnings: Wider-Than-Expected Loss of -$0.13 Weighs on SharesEarnings Per Share - vinanet.vn
Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
TherapeuticsMD (TXMD) Holds Steady at $2.03 as Trading Range NarrowsVolume Rate Change - dars.gov.et
TXMD|TherapeuticsMD Inc|Price:2.090|Chg%:+0.060 - TradingKey
TherapeuticsMD Inc. (TXMD) Slips Further: Key Support Levels Under PressurePCR Spike - dars.gov.et
TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA - TradingView
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Cash Flow - TradingKey
TherapeuticsMD (TXMD) Holds Steady Near Key Support With Slight UptickProfitability Factor - dars.gov.et
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD, Inc. Revenue Breakdown – MUN:29TA - TradingView
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.060| - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.070| - TradingKey
TherapeuticsMD (TXMD) Holds Steady at $2.06 as Consolidation ContinuesPut Support - dars.gov.et
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):